Numerai GP LLC Purchases Shares of 6,821 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Numerai GP LLC acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 6,821 shares of the company’s stock, valued at approximately $2,820,000. IDEXX Laboratories makes up 0.8% of Numerai GP LLC’s holdings, making the stock its 16th largest position.

A number of other institutional investors also recently modified their holdings of IDXX. Czech National Bank grew its holdings in IDEXX Laboratories by 5.9% during the 4th quarter. Czech National Bank now owns 17,755 shares of the company’s stock worth $7,341,000 after acquiring an additional 989 shares during the last quarter. Miracle Mile Advisors LLC bought a new stake in shares of IDEXX Laboratories during the fourth quarter valued at approximately $201,000. Signal Advisors Wealth LLC increased its holdings in shares of IDEXX Laboratories by 25.7% in the fourth quarter. Signal Advisors Wealth LLC now owns 967 shares of the company’s stock valued at $400,000 after purchasing an additional 198 shares in the last quarter. Oak Thistle LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at approximately $426,000. Finally, Crestmont Private Wealth LLC raised its position in IDEXX Laboratories by 17.3% in the 4th quarter. Crestmont Private Wealth LLC now owns 616 shares of the company’s stock worth $255,000 after purchasing an additional 91 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Bank of America lifted their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Piper Sandler upped their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Stifel Nicolaus lowered their price target on shares of IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating for the company in a research report on Monday, April 14th. Barclays increased their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Finally, StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday, May 9th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $524.75.

IDEXX Laboratories Stock Down 0.1%

Shares of NASDAQ:IDXX opened at $509.13 on Wednesday. The company has a 50 day moving average price of $426.36 and a two-hundred day moving average price of $429.96. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The company has a market capitalization of $40.95 billion, a PE ratio of 47.72, a PEG ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $548.88.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating analysts’ consensus estimates of $2.93 by $0.03. The business had revenue of $998.43 million during the quarter, compared to analysts’ expectations of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.71 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.